Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
AssigneesBaxter Healthcare S.A., Baxter International Inc.
InventorsNorman R. Relkin, Larry Backes, Richard Schiff
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of the level of certain cytokines in a patient's blood as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen. Methods for treating Alzheimer's disease and monitoring therapeutic effectiveness are provided.
Claims25
A method for treating Alzheimer's disease in a subject in need thereof, comprising the sequential steps of:
- (a) determining the amount of a cytokine in the subject's blood, thereby obtaining a baseline value of the cytokine level;
- (b) administering a brain preserving therapeutic agent to the subject for the purpose of treating Alzheimer's disease during a first time period;
- (c) determining the amount of the cytokine in the subject's blood, thereby obtaining a first intermediate value of the cytokine level;
- (d) comparing the intermediate value from step (c) with the baseline value from step (a);
- and
- (e) increasing administration of the brain preserving therapeutic agent in dose or frequency when step (d) indicates no increase from the baseline value to the first intermediate value, or maintaining administration of the brain preserving therapeutic agent in dose or frequency when step (d) indicates an increase from the baseline value to the first intermediate value.
A method for assessing efficacy of a therapy intended for treating Alzheimer's disease, comprising the steps of:
- (a) determining the average level of a cytokine in the blood of subjects suffering from Alzheimer's disease but not receiving the therapy, thereby obtaining a non-therapeutic level of the cytokine;
- (b) determining the average level of the cytokine in the blood of subjects suffering from Alzheimer's disease and receiving the therapy, thereby obtaining a therapeutic level of the cytokine;
- and
- (c) comparing the therapeutic level with the non-therapeutic level, thereby determining the efficacy of the therapy,
- wherein the therapy is deemed effective when the therapeutic level is higher than the non-therapeutic level, and the therapy is deemed ineffective when the therapeutic level is equal to or lower than the non-therapeutic level.
Dependencies are inferred from the claim text.